Who is sponsoring NCT05633680?

NCT05633680 is sponsored by Handan First Hospital.

What drugs are being tested in NCT05633680?

Interventions in NCT05633680: Peripheral blood sampling for circulating tumor cells.

What condition does NCT05633680 study?

NCT05633680 studies Breast Neoplasm, Neoplastic Cells, Circulating.

Is NCT05633680 still recruiting?

NCT05633680 is currently status unknown. Last updated 13 March 2023.

Last reviewed 2023-03-13 · How we verify

NCT05633680: CTCSFBC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Circulating Tumor Cells Screen for Breast Cancer

Status unknown Last updated 13 March 2023

What this trial tests

trial testing Peripheral blood sampling for circulating tumor cells in Breast Neoplasm in 200 participants. Status unknown.

Timeline

20 February 2020

Primary endpoint
20 April 2023

20 June 2023

Quick facts

Lead sponsor	Handan First Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	20 February 2020
Primary completion	20 April 2023
Estimated completion	20 June 2023
Sites	1 location across China

Drugs / interventions tested

Peripheral blood sampling for circulating tumor cells

Conditions studied

Breast Neoplasm — all drugs for Breast Neoplasm →
Neoplastic Cells, Circulating — all drugs for Neoplastic Cells, Circulating →

Sponsor

Handan First Hospital

Who can join

Adults 18 to 85, female only, with Breast Neoplasm or Neoplastic Cells, Circulating. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective study was used to collect patients considering breast cancer admitted to our general surgery department from 2019-6 to 2023-8, to identify the case group (breast cancer) and the control group (non-breast cancer), to compare the differences in CTC in peripheral blood between the two groups, and to draw conclusions after statistical analysis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y
Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review).
Rusnáková DŠ, Aziri R, Dubovan P, Jurík M, et al · · 2025 · cited 3× · PMID 39492933 · DOI 10.3892/ol.2024.14756
Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.
Ma S, Wang X, Lin PP, Lei L. · · 2025 · cited 1× · PMID 40437761 · DOI 10.1002/cam4.70902

Verify or expand the search:

Other recruiting trials for Breast Neoplasm

Currently open trials in the same condition.

NCT07054723 — Surviving Daily Life · recruiting
NCT06839001 — CRYoablation for Small Tumors As Local Treatment - SIX Trial · Phase 3 · recruiting
NCT06672302 — A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify · recruiting
NCT06255808 — Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor · active not recruiting
NCT06622967 — KNUCH CadAI-B-1(KCB-1) · NA · active not recruiting

Other Handan First Hospital trials

Trials by the same sponsor.

NCT06175156 — Application of Propofol Mixed With Remifentanil in Fiber Colonoscopyand Analgesia in Fiber Colonoscopy · NA · completed
NCT05712785 — Shuotongo Ureteroscopy for Upper Urinary Tract Stones · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05633680 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Handan First Hospital
Last refreshed: 13 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05633680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing